Assoc. Prof. Dr. Florian Kopp

/

• Journal Articles

  1.     Tenjović B, Bekić S, Ćelić A, Petri E, Scholda J, Kopp F*, Sakač M, Nikolić A. Synthesis and biological evaluation of novel D-ring fused steroidal N(2)-substituted-1,2,3-triazoles. RSC Med Chem. (2024) DOI: 10.1039/D4MD00297K

  2.     Sánchez V, Baumann A, Kromm F, Yergaliyev T, Brandt A, Scholda J, Kopp F, Camarinha-Silva A, Bergheim I. Oral supplementation of choline attenuates the development of alcohol-related liver disease (ALD). Mol Med. (2024) DOI: 10.1186/s10020-024-00950-4

  3.     Burger K, Jung F, Staltner R, Csarmann K, Schweiger K, Brandt A, Baumann A, Scholda J, Kopp F, Bergheim I. A weekly 4-methylpyrazole treatment attenuates the development of non-obese metabolic dysfunction-associated steatotic liver disease (MASLD) in male mice: Role of JNK. Eur J Clin Invest. (2025) DOI: 10.1111/eci.14320

  4.     Brandt A, & Kopp, F*. Long Noncoding RNAs in Diet-Induced Metabolic Diseases. Int J Mol Sci (2024) DOI: 10.3390/ijms25115678

  5.     Janković ÐD, Šestić TL, Bekić SS, Savić MP, Ćelić AS, Scholda J, Kopp F*, Marinović MA, Petri ET, Ajduković JJ. Development of new steroid-based hydrazide and (thio)semicarbazone compounds with anticancer properties. J Steroid Biochem Mol Biol. (2024) DOI: 10.1016/j.jsbmb.2024.106545

  6.     Scholda J, Nguyen TA and Kopp F*. Long noncoding RNAs as versatile molecular regulators of homeostasis and cellular stress response. Hum Genet. (2024) DOI: 10.1007/s00439-023-02604-7

  7.     Decker S, Taschauer A, Geppl E, Pirhofer V, Schauer M, Pöschl S, Kopp F, Richter L, Ecker GF, Sami H, Ogris M. Structure-based peptide ligand design for improved epidermal growth factor receptor targeted gene delivery. Eur J Pharm Biopharm. (2022) DOI: 10.1016/j.ejpb.2022.05.004

  8.     Kopp F*. Molecular functions and biological roles of long noncoding RNAs in human physiology and disease. J Gene Med. (2019) DOI: 10.1002/jgm.3104

  9.     Elguindy MM, Kopp F, Goodarzi M, Rehfeld F, Thomas A, Chang TC, Mendell JT. PUMILIO, but not RBMX, binding is required for regulation of genomic stability by noncoding RNA NORAD. eLife. (2019) DOI: 10.7554/eLife.48625

  10.  Kopp F, Elguindy MM, Yalvac ME,Zhang H, Chen B, Gillett FA, Lee S, Sivakumar S, Yu H, Xie Y, Mishra P, Sahenk Z, Mendell JT. PUMILIO hyperactivity drives premature aging of Norad-deficient mice. eLife. (2019) DOI: 10.7554/eLife.42650

  11.  Kopp F and Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. (2018) DOI: 10.1016/j.cell.2018.01.011

  12.  Golden RJ, Chen B, Tuo L, Braun J, Manjunath H, Chen X, Wu J, Schmid V, Chang TC, Kopp F, Ramirez-Martinez A, Tagliabracci VS, Chen ZJ, Xie Y, Mendell JT. An Argonaute phosphorylation cycle promotes microRNA-mediated silencing. Nature. (2017) DOI: 10.1038/nature21025

  13.  Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. (2016) DOI: 10.1016/j.cell.2015.12.017

  14.  Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A. Sequential salinomycin treatment results in resistance formation through clonal selection of epithelial-like tumor cells. Transl Oncol. (2014) DOI: 10.1016/j.tranon.2014.09.002

  15.  Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E, Roidl A. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. (2014) DOI: 10.1186/1476-4598-13-16

  16.  Kopp F, Wagner E, Roidl A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget. (2014) DOI: 10.18632/oncotarget.1427

  17.  Kopp F, Schnoedt M, Haase R, Wagner E, Roidl A, Ogris M. De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells. Gene Ther. (2013) DOI: 10.1038/gt.2013.37

  18.  Haase R, Magnusson T, Su B, Kopp F, Wagner E, Lipps H, Baiker A, Ogris M. Generation of a tumor- and tissue-specific episomal non-viral vector system. BMC Biotechnol. (2013) DOI: 10.1186/1472-6750-13-49

  19.  Kopp F, Oak PS, Wagner E, Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One. (2012) DOI: 10.1371/journal.pone.0050469

  20.  Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. (2012) DOI: 10.1002/ijc.27595